Company Overview and News

0
SHREE CEMENT LIMITED - Updates

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

0
Broker's call: Shree Cement (Buy)

2018-07-10 thehindubusinessline
Shree Cement (SCL) gained 1.87 per cent on Tuesday after rising 3 per cent on Monday on the expectation of healthy traction ahead due to sustained demand improvement and visible realisation recovery.
HCLTECH 500387 IDEA HCTHY 532281 ICLQY 532822 SHREECEM

0
SHREE CEMENT LIMITED - Updates

2018-07-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

0
SHREE CEMENT LIMITED - Shareholders meeting

2018-07-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

0
SHREE CEMENT LIMITED - Updates

2018-07-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

0
SHREE CEMENT LIMITED - Updates

2018-06-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

0
SHREE CEMENT LIMITED - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

24
Market Update: RIL top Nifty gainer, hits new record high; ICICI, Indigo up 1-2%, Infratel down 3%

2018-06-21 moneycontrol
The broader indices including the Nifty and the Sensex are trading on a positive note this Thursday morning with the Nifty up 7 points at 10,779 and the Sensex is trading higher by 31 points at 35,578.
SUZLON 500325 TCHQY 532514 532755 SHREECEM IGL 534816 SUEL RLNIY 524804 TATAPOWER APOLLOTYRE AYRQY 532667 TECHM BATAINDIA TATASTEEL TATLY 500180 500387 BHRYY AUROPHARMA GODREJIND RELIANCE 500470 532461 RIGD INFRATEL HDFCBANK INDIGO 517354 HVLQY 500877 IBN 539207 539448 ICICIBANK TTST PNJZY HDB 532174 ARBQY HAVELLS TPCL PNB 500400 500043 500164 MANPASAND

0
SHREE CEMENT LIMITED - Updates

2018-06-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

0
Shree Cement plans to close United Cement deal by July

2018-06-10 livemint
Kolkata: Shree Cement Ltd, one of India’s top three cement makers, has budgeted for a capital expenditure of ₹3,500 crore in the current financial year, which includes ₹2,000 crore to be spent to conclude the acquisition of a United Arab Emirates-based (UAE) firm.
EMKAY 500387 532737 SHREECEM

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...